Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS)

SIMPLE SUMMARY: Activation of YAP/TAZ (mediators of Hippo signaling) is associated with the development of liver cancer. The expression level of YAP is known to relate to chemoresistance. However, the therapeutic effect of YAP/TAZ inhibition when combined with sorafenib and conventional chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Sojung, Lim, Ji Yeon, Cho, Kyungjoo, Lee, Hye Won, Park, Jun Yong, Ro, Simon Weonsang, Kim, Kyung Sik, Seo, Haeng Ran, Kim, Do Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179573/
https://www.ncbi.nlm.nih.gov/pubmed/35681712
http://dx.doi.org/10.3390/cancers14112733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179573/
https://www.ncbi.nlm.nih.gov/pubmed/35681712
http://dx.doi.org/10.3390/cancers14112733

Ejemplares similares